Researchers from the University of Nottingham developed the synthetic compound which inhibits a pain-sensing pathway in the spinal cord known as the cannabinoid receptor 2 (CB2).
Although cannabis can effectively relieve pain, its use in medicine is limited because of its other psychological effects.
The compound, called JWH133, is completely synthetic but is designed to selectively target CB2 in a similar way to the drug.
Levels of the CB2 receptor in the spinal cord have been shown to be closely linked to the severity of pain among osteoarthritis sufferers, 'The Telegraph' reported.
There is no effective drug treatment to slow the progression of the condition, but interventions include pain relief, exercise, physiotherapy, weight loss and joint replacement.
"This finding is significant, as spinal and brain pain signalling pathways are known to make a major contribution to pain associated with osteoarthritis," said Professor Victoria Chapman, who led the study.
"These new data support the further evaluation of the selective cannabinoid-based interventions for the treatment of osteoarthritis pain," she said.
The study was published in the Public Library of Science ONE journal.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
